If you have been watching Sarepta Therapeutics (SRPT), this week's headlines have probably caught your eye. Multiple law firms have announced class action lawsuits against the company, following ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without ...

Sarepta Therapeutics obtained traditional FDA approval for ambulatory DMD patients and accelerated approval for ...

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...

The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.

Sarepta’s flagship product, Elevidys, is a gene therapy for DMD that has shown promising results in clinical trials. The company also boasts a portfolio of FDA-approved exon-skipping therapies, ...

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

Despite rocky road with its DMD gene therapy, Sarepta Therapeutics hands in $30 million to Lacerta in exchange for a group of CNC therapies.